MIRO News and Press, Miromatrix Medical Inc. From 03/07/23

EDEN PRAIRIE, Minn., March 07, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that i...

Miromatrix Medical ( NASDAQ: MIRO ) announced Wednesday that Baxter International ( NYSE: BAX ) has partnered with it to develop a new liver therapy comprising the company's single-use bioengineered liver miroliverELAP with Baxter's continuous renal replacement therapy PrisMax sys...

Combines Miromatrix’s expertise in bioengineered organs with Baxter’s leadership in critical care delivery and organ support therapies Includes intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients suffering fr...

EDEN PRAIRIE, Minn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today provided a program update on miroliver ELAP™...

EDEN PRAIRIE, Minn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that it was informed via e-mail from the U....

EDEN PRAIRIE, Minn., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will participate in ...

Miromatrix Medical Inc. (MIRO) Q3 2022 Results Conference Call November 14, 2022 04:30 PM ET Company Participants Hannah Jeffrey - IR Jeff Ross - CEO Jim Douglas - CFO Presentation Operator Greetings, and welcome to the Miromatrix Medical Inc....

Miromatrix Medical press release ( NASDAQ: MIRO ): Q3 GAAP EPS of -$0.37 beats by $0.03 . Revenue of $0.01M (-90.0% Y/Y) beats by $0.01M . For further details see: Miromatrix Medical GAAP EPS of -$0.37 beats by $0.03, revenue of $0.01M beats by $0.01M

EDEN PRAIRIE, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2022 financial results a...

Presentation Times and Weblinks Released for Over 35 Presenting Companies Wednesday and Thursday, November 9-10, 2022 NEW YORK, NY / ACCESSWIRE / November 8, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Co...